Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of SSGJ-608 in Healthy Subjects
NCT04367441Phase 1Unknown
- Sponsor
- 3S Guojian Pharmaceutical
- Start
- Nov 2019
- Primary completion
- Oct 2020
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in plaque psoriasis comparing SSGJ-608 with Placebo (2 arms). Primary endpoint: Number of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs) up to 91 days. Status: unknown.
02
Drugs
608
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on NCT04367441.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04367441.